The Patient-Centered Outcomes Research Institute (PCORI) announced on April 28, 2026 that it has awarded funding, close to $10 million according to Johns Hopkins Bloomberg School of Public Health, for a trial that will compare two dementia caregiver support programs directly against each other rather than against a waitlist or usual-care group. The multicenter, cluster-randomized noninferiority trial, led by Lauren Parker of the Johns Hopkins Bloomberg School of Public Health, will measure caregiver depressive symptoms using the 20-item Center for Epidemiologic Studies Depression Scale (CES-D) as its primary outcome, according to PCORI's own award listing. Nearly 500 caregivers recruited through community adult day service centers across the United States are expected to take part, per the Johns Hopkins announcement.
The two programs being compared are ADS Plus, delivered face to face by trained adult day service staff, and Plans4Care, a self-guided web-based version of similar caregiver education and problem-solving content, PCORI's listing states. ADS Plus already has evidence behind it: a 34-site cluster-randomized trial of 203 caregivers, published in The Gerontologist in 2024, found that caregivers who received ADS Plus reported fewer depressive symptoms than those receiving adult day services alone by 12 months. What has not been tested until now is whether the newer, self-guided digital version delivers similar benefit without the staff-intensive, in-person model, which is the specific question this PCORI-funded trial is designed to answer.
The study is a noninferiority design, meaning its stated goal is to determine whether the digital tool performs no worse than the in-person program, not necessarily whether either one outperforms the other on depressive symptoms. The project team includes staff from Plans4Care, the company that develops and licenses the digital program under study, and whose co-founder also helped develop ADS Plus, according to the Johns Hopkins release; PCORI's public listing does not detail how that relationship will be managed within the trial's independent analysis.